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all 12 features were associated with IDS satisfaction (P < 0.01),
but only discrepancy scores for “easy to control blood sugar,”
“reduces my reluctance to use insulin,” “easy to get insulin dose
needed,” and “convenient to use” were signiﬁcant predictors of
IDS satisfaction, as were HbA1C and health status (R2 = 0.31;
P < 0.05).CONCLUSION: IDS features are important to patients
with T2DM; therefore resolving discrepancies between feature
importance and patient evaluation of IDS features may improve
patient satisfaction and facilitate diabetes management.
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OBJECTIVE: Understanding what Insulin Delivery System (IDS)
features are important to patients with type 2 diabetes (T2DM) is
essential to the development of improved IDSs. The objective of
this study was to determine what characteristics are associated
with (or predict) users of insulin pens vs. vial and syringe
(V/S). METHODS: Patients with T2DM were administered a
web-based survey that included questions about demographics,
comorbidities, glycemic control, and insulin use; ratings of the
importance of 12 IDS features; and an evaluation of features of the
current IDS. Two logistic regression analyses were performedwith
the respondent characterization of their IDS as insulin pen or V/S
as dependent variables. Variables signiﬁcantly (p < 0.05) associ-
ated with dependent variables, a priori, were included as indepen-
dent variables. RESULTS: A total of 681 insulin-using
T2 patients in the US (52% female; mean age = 57 years; 88%
Caucasian; 85% on insulin >1 year, 86% used V/S) participated in
the survey. Signiﬁcant predictors (p < 0.05) for insulin pen use:
Patient: “is a homemaker” (OR, 0.177), “agrees their IDS does
not interfere with plans for short trips” (OR, 5.942), “agrees their
IDS is easy to carry away from home” (OR, 0.054), “rates their
IDS ease to carry away from home as ‘important’” (OR, 2.558),
“uses Byetta” (OR, 0.067), “injects insulin >twice/day” (OR,
0.235), “has never been diagnosed with depression” (OR, 0.367).
Signiﬁcant predictors (p < 0.05) of V/S use: Patient: “is dissatisﬁed
with their IDS regarding insulin use” (OR, 111.767), “disagrees
their IDS makes it easy getting ready for next dose” (OR, 0.006),
“has cancer” (OR, <0.0001), “uses Glargine” (OR, <0.0001), “is
not using insulin lispro” (OR, 0.013), “has a higher number of
adults in the household”, “rates IDS discreetness as ‘least impor-
tant’ ” (OR, 206.347). CONCLUSION: Overall, multiple injec-
tions and need for portability predict insulin pen use; not valuing
discreteness and dissatisfaction predict V/S use.
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OBJECTIVE: To examine the effects of sociodemographic
characteristics, health status, comorbidity, provider, medication
and ﬁnancial variables on insulin initiation behavior for type 2
diabetics on multiple oral antidiabetic medications. METHODS:
The 2002–2006 MarketScan Research Databases were used to
study the health care utilization and expenditure patterns of
adults with type 2 diabetes in employer-sponsored health plans in
the United States. The utilization patterns of 38,768 patients
with Type 2 diabetes who were adherent to one oral antidiabetic
medication and added a second oral medication for at least 6
months were analyzed. Two outcomes were examined: insulin
initiation within 12 months and the amount of time to insulin
initiation. Multivariate logistic models were used to estimate the
effects of the explanatory variables on the likelihood of insulin
initiation. Cox proportional hazard models with prescription
drug and ofﬁce visit copayments as time-varying covariates were
used to estimate the effects of the explanatory variables on the
amount of time to insulin initiation. RESULTS: A total of 16.5%
of patients initiated insulin within one year. A variety of deter-
minants were associated with insulin initiation within a year: age
(Adjusted Odds Ratio 0.982, 95% CI (0.980, 0.985) ), health
status indicated by the presence of factors such as heart disease
(AOR 1.48 (1.317, 1.654)), myocardial infarction (AOR 1.32,
(1.068, 1.640)), diabetic retinopathy (AOR 1.26, (1.120,
1.406)), the number of nondiabetes medications (AOR 1.03,
(1.030, 1.039)), and insulin copayments (AOR 0.998, (0.995,
1.000)). The amount of time to insulin initiation was also
affected by similar factors. CONCLUSION: Health status
appears to be the strongest predictor of insulin initiation in
patients initiating insulin for type 2 diabetics who are adherent to
oral medications. Providers, health plans and employers should
be aware of the factors that inﬂuence the addition of a medica-
tion to a treatment regimen for chronically-ill patients.
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OBJECTIVE: To evaluate the one to two year changes in health
care costs and disease-related process measures associated with
the a disease management program initiated in 2002 for
higher-risk, higher-expenditure adult fee-for-service Medicaid
clients with diabetes in the State of Colorado, United States.
METHODS: This retrospective database analysis employed a
pre-post and propensity-score matched analysis assessing direct
costs from the perspective of a public payer. Data analyzed
included comprehensive medical and pharmacy claims, patient
demographics (i.e., age, gender, race), medical and pharmacy
resource utilization claims (e.g., selected prescription drug use
and laboratory testing procedures conducted), diagnostic
information, and eligibility/enrollment status. Multivariate re-
gression techniques were utilized to ascertain differences between
the disease management and matched comparator groups.
RESULTS: Of the 388 Medicaid clients that were eligible and
initially contacted for enrollment, 41 (11%) completed at least
one year and 10 (3%) completed an entire two years of the
program. Enrollees were typically older, female, and of a non-
white race or ethnicity. Among those enrolled for one year or
more, signiﬁcant decreases in overall medical costs were observed
relative to matched comparators during both Year 1 and Year 2
of the interventions (Year 1 = 44.4% decrease, p < 0.001 and
Year 2 = 67.1% decrease, p < 0.010). Overall pharmacy costs
were lower for the disease management group during Year 2
(64.0% decrease, p = 0.013), as were diabetes-related pharmacy
costs (64.9%, p = 0.005). Effect sizes based upon multivariate
analyses were observed to be small. CONCLUSION: Based on
this analysis of 41 clients completing at least one year of diabetes
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